Who are Leflunomide(LEF)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leflunomide 10 milligram (MG), IMU-838 tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/leflunomide-lef.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Leflunomide(LEF) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Leflunomide(LEF) (Leflunomide(LEF)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant; DHODH inhibitor. Area: Immunology; Rheumatology.

marketed Immunosuppressant; DHODH inhibitor Dihydroorotate dehydrogenase (DHODH) Immunology; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Leflunomide(LEF) (Leflunomide(LEF)) — Nanjing Children's Hospital. Leflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby suppressing T-cell and B-cell proliferation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Leflunomide(LEF) TARGET	Leflunomide(LEF)	Nanjing Children's Hospital	marketed	Immunosuppressant; DHODH inhibitor	Dihydroorotate dehydrogenase (DHODH)
Leflunomide 10 milligram (MG)	Leflunomide 10 milligram (MG)	P. Verschueren	marketed	DHODH inhibitor; disease-modifying antirheumatic drug (DMARD)	Dihydroorotate dehydrogenase (DHODH)
IMU-838 tablets	IMU-838 tablets	Immunic AG	phase 3	DHODH inhibitor	Dihydroorotate dehydrogenase (DHODH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant; DHODH inhibitor class)

Nanjing Children's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leflunomide(LEF) — Competitive Intelligence Brief. https://druglandscape.com/ci/leflunomide-lef. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing